CatalystWireBeta

UK small-cap RNS · 9 Dec 2025

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies
  1. 07:00
    Sale of Non-Core Products
    Sale of non-core products for up to £4.5m in cash on a cash free, debt free basis
    +2.1% on the day
  2. 07:00
    Greenland Government Grants Exploitation Licence
    GreenRoc Strategic Materials Plc / EPIC: GROC / Market: AIM / Sector: Mining
    first in 6 months +4.0% on the day
  3. 07:00
    Transaction in Own Shares Routine
  4. 07:00
    Issue of Equity - Result of WRAP Retail Offer Routine
  5. 07:00
    Half-year Results Results
    Interim results contain no numerical guidance, so there is nothing to raise. Management only voices confidence in 2026 and expects proposals to convert, which restates the existing tone.
    outlook positivefirst in 7 months +2.3% on the day
    Moved: Global advisory firm contract rollout: Contract signed; monthly subscription started → Contract confirmed as a new vertical win · new: Digital assets and AI investment pivot – Advisers appointed, opportunities being evaluated
  6. 07:00
    Replacement LendInvest H1 FY26 Financial Statement
    New lending up 23% to £663.6m, led by Buy-to-Let and product transfers with no rise in fixed overheads, supporting the operating-leverage case behind the second consecutive profitable half.
    in lineoutlook positive4 business updates in 3 months – usually about 1 +0.0% on the day
  7. 07:00
    Ixico IXI £22m
    Financial Results for year ended 30 September 2025 Results
    The order book rose 27% in two months to £17.7m, reversing the fall to £13.8m at year-end (£15.3m in 2024), after the HD and Alzheimer's wins. This improves revenue visibility.
    outlook positive3 business updates in 3 months – usually less than 1 +14.0% on the day
  8. 07:00
    Half-year Results Results
    Half year results for the 26 weeks ended 29 September 2025 (HY26)
    in linefirst since Oct 2023 +2.2% on the day
  9. 07:00
    Strong Lettings Progress At The Centro Buildings
    Workspace Group PLC ('Workspace'), London's leading provider of sustainable, flexible workspace, has signed a new five-year lease agreement with the North London NHS Foundation Trust at The Centro Buildings in Camden.
    −0.7% on the day
  10. 07:00
    Electricity Generation and Revenues Surge
    Electricity Generation and Revenues Surge at Pyebridge 8.1 MW FlexGen Power Asset
    +6.4% on the day
  11. 07:00
    Transaction in Own Shares Routine
  12. 07:00
    Transaction in Own Shares Routine
  13. 07:00
    Transaction in Own Shares and Total Voting Rights Routine
  14. 07:00
    Results for the year ended 31 October 2025 Results
    Board only says 2026 operating performance expectations 'remain unchanged'; this confirms guidance and is not a raise. Higher capex and finance charges from Norway investment are a minor offset.
    outlook positivefirst in 6 months −0.6% on the day
    Moved: UK Government order placement delays: Delays continuing; S&I cover c.47% for FY26 → Delays continue; S&I revenue down 18% · Landguard integration into Roke: Acquisition completed 29 August 2025; integrating → Acquired; £2.5m Roke restructuring booked · Alloy Surfaces strategic review: Strategic options being assessed; reported as discontinued → Reported as discontinued operation
  15. 07:00
    Half-year Results Results
    Revenue up 13% and pre-IFRS16 adjusted EBITDA up 15% with a narrower loss, but Boom LFL fell 6.8% and free cash generation dropped 19%, so growth is partly acquired and consumer demand is soft.
    Disposal of a part (break-up) £20.0m · 78% of mcapoutlook mixedfirst in 1 year −6.5% on the day
    Moved: Expand UK footprint through owned sites and franchising.: pending → on_track – New Escape Hunt sites opened in Canterbury and Sheffield, a Boom opened in Reading, and further sites are in discussion. · Double pre-IFRS 16 Group Adjusted EBITDA by March 2028.: pending → on_track – Pre-IFRS16 Group Adjusted EBITDA rose 15% to £1.7m in H1, though the base is small. · Reach £100m run-rate sales and £15m adjusted EBITDA by March 2028.: pending → on_track – The company still sees a medium-term opportunity to reach £100m run-rate turnover and £15m EBITDA.
  16. 07:00
    AGM Statement
    I am very pleased to provide a short update for shareholders ahead of our AGM today as we continue to work towards wider adoption of the KidneyintelX.dkd test, the first FDA-approved advanced prognostic blood test with Medicare reimbursement coverage, to …
    −7.4% on the day
  17. 07:00
    Transaction in Own Shares Routine
  18. 07:00
    Pre-close Statement Trading update
    Pre-close: South African production is guided above range and FOB costs below range, but benchmark coal prices are well down. PPE carrying values are flagged as unsupported, so an impairment may follow, and 2026 production is guided 0.5Mt lower.
    Disposal of a part (break-up) ahead of expectationsoutlook mixed +3.1% on the day
    Moved: Goedehoop North disposal: Agreement signed; conditions precedent outstanding → Agreement signed; awaiting completion · new: Kleinkopje mining right disposal – Agreement finalised; awaiting completion · new: PPE carrying value impairment assessment – Assessment under way; carrying values unsupported
  19. 07:00
    Transaction in Own Shares Routine
  20. 07:00
    Transaction in Own Shares Routine
  21. 07:00
    Transaction in Own Shares Routine
  22. 07:00
    Transaction in Own Shares Routine
  23. 07:00
    Half-year Results Results
    Revenue up 9.3% (8.6% organic) on better pricing and utilisation, but underlying PBT fell 10.8% and margin slipped to 9.2% on pre-Budget slowdown and investment; full-year consensus is reiterated.
    Turnaround plan with targets £5.7m · 6% of mcapin lineoutlook positive +4.9% on the day
    Moved: new: Margin improvement to 13.5% – H1 margin 9.2%; investment ongoing
  24. 07:00
    Transaction in Own Shares Routine
  25. 07:00
    Transaction in Own Shares Routine
  26. 07:00
    Transaction in Own Shares Routine
  27. 07:00
    Playtech PTEC £1,036m
    Transaction in Own Shares Routine
  28. 07:00
    La India Development Update
    The rule label 'production up' is a loose reading: this is a development update, not production. La India construction is 24% complete against a 20% forecast, and first gold is still targeted for Q4 2026, funded from Runruno cash flow.
    Project milestones outlook positive +0.0% on the day
    Moved: La India construction: Construction progressing → 24% complete, ahead of schedule; first gold Q4 2026
  29. 07:00
    Transaction in Own Shares Routine
  30. 07:00
    Transaction in Own Shares Routine
  31. 07:00
    Continued improvement in PFS with iSCIB1+
    Updated SCOPE Phase 2 data show PFS holding at 74% at 16 months in the target HLA population versus 50% at 11.5 months for standard of care, supporting the move to late-stage trials.
    Project milestones outlook positive −4.4% on the day
    Moved: iSCIB1+ melanoma registration path: Phase 2 data presented; development accelerated → Regulator feedback aligned; Phase 3 planning, partnering and financing under way
  32. 07:00
    Transaction in Own Shares Routine
  33. 07:00
    Transaction in Own Shares Routine
  34. 07:00
    Transaction in Own Shares Routine
  35. 07:00
    Transaction in Own Shares Routine
  36. 07:00
    AGM Statement & Trading Update Trading update
    ("COF") of the Republic of Korea, ahead of the Company's annual general meeting ("AGM") to be held later this morning.
    +3.4% on the day
  37. 07:00
    Transaction in Own Shares and Total Voting Rights Routine
  38. 07:00
    Transaction in Own Shares Routine
  39. 07:00
    IWG IWG £1,745m
    Transaction in Own Shares Routine
  40. 07:00
    Transaction in Own Shares Routine
  41. 07:00
    Transaction in Own Shares Routine
  42. 07:00
    Transaction in Own Shares Routine
  43. 07:00
    Transaction in Own Shares Routine
  44. 07:00
    Transaction in Own Shares Routine
  45. 07:00
    Half-year Results Results
    for the six months ended 31 October 2025
    in linefirst since Oct 2023 −0.5% on the day
  46. 07:00
    Conversion of CLNs
    Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that the Company has received notices, in two tranches, to convert a total face value of £80,000 convertible loan notes (the "CLNs") resulting in the issue of 6,282,264 new …
    −3.7% on the day
  47. 07:00
    Transaction in Own Shares Routine
  48. 07:00
    Trading Update Trading update
    Applied Nutrition plc (LSE: APN), a leading sports nutrition, health and wellness brand, today announces an update on trading for the current financial year ending 31 July 2026 ("FY26").
    Upgrade / downgrade cycle ahead of expectations +10.1% on the day
  49. 07:00
    Transaction in Own Shares Routine
  50. 07:00
    Transaction in Own Shares Routine
  51. 07:00
    Transaction in Own Shares Routine
  52. 07:00
    Transaction in Own Shares Routine
  53. 07:00
    Transaction in Own Shares Routine
  54. 07:00
    Transaction in Own Shares Routine
  55. 07:00
    Transaction in Own Shares Routine
  56. 07:00
    Transaction in Own Shares Routine
  57. 07:00
    Transaction in Own Shares Routine
  58. 07:00
    Transaction in Own Shares Routine
  59. 07:00
    Half-year Results Results
    Guidance is only confirmed: trading is in line with expectations and full-year expectations are unchanged, so this is not an upgrade.
    in lineoutlook positivefirst since Oct 2023 −1.2% on the day
    Moved: new: Experiences repositioning – H1 revenue down 8.9%; early H2 improved · new: FY26 share buybacks – £30.0m H1 done; second half to follow
  60. 07:00
    Transaction in Own Shares Routine
  61. 07:00
    Transaction in Own Shares Routine
  62. 07:00
    Transaction in Own Shares Routine
  63. 07:00
    Transaction in Own Shares Routine
  64. 07:00
    Transaction in Own Shares Routine
  65. 07:00
    Annual General Meeting Statement
    Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer publishes an update on operations and pipeline progress ahead of its Annual …
    first since Oct 2023 +0.0% on the day
  66. 07:00
    Exercise of Option to Acquire Crofton Gold Project
    Cloudbreak Discovery Plc (LSE: CDL), a London Stock Exchange Main Market listed company, is pleased to announce that it has decided to exercise the option to acquire exploration licence application E45/6690 covering 57km² (Figure1 ) known as the Crofton Gold …
    +3.7% on the day
  67. 07:00
    Transaction in Own Shares Routine

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note